Evidence map›Paper›PMID 39271657›Full record

ArticleNature communications2024

Pro-efferocytic nanotherapies reduce vascular inflammation without inducing anemia in a large animal model of atherosclerosis.

Sharika Bamezai, Yapei Zhang, Manisha Kumari, Mozhgan Lotfi, Tom Alsaigh, Lingfeng Luo, Gayatri Suresh Kumar, Fudi Wang, Jianqin Ye, Madhu Puri and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Review
  2. Nanomaterials-Based Immunotherapy for Atherosclerosis.Small (Weinheim an der Bergstrasse, Germany) · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Sharika Bamezai *Department of Surgery, Division of Vascular Surgery, Stanford University School of Medicine, Stanford, CA, USA.
Yapei Zhang *Department of Biomedical Engineering, Michigan State University, East Lansing, MI, USA.
Manisha Kumari *Department of Biomedical Engineering, Michigan State University, East Lansing, MI, USA.
Mozhgan LotfiDepartment of Surgery, Division of Vascular Surgery, Stanford University School of Medicine, Stanford, CA, USA.
Tom AlsaighDepartment of Surgery, Division of Vascular Surgery, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0009-0003-1037-302X
Lingfeng LuoDepartment of Surgery, Division of Vascular Surgery, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-0601-0053
Gayatri Suresh KumarDepartment of Surgery, Division of Vascular Surgery, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0003-4636-7740
Fudi WangDepartment of Surgery, Division of Vascular Surgery, Stanford University School of Medicine, Stanford, CA, USA.
Jianqin YeDepartment of Surgery, Division of Vascular Surgery, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0003-4492-3897
Madhu PuriDepartment of Biomedical Engineering, Michigan State University, East Lansing, MI, USA.
Romila ManchandaDepartment of Biomedical Engineering, Michigan State University, East Lansing, MI, USA.
Sesha PaluriDepartment of Biomedical Engineering, Michigan State University, East Lansing, MI, USA.
Shaunak S AdkarDepartment of Surgery, Division of Vascular Surgery, Stanford University School of Medicine, Stanford, CA, USA.
Yoko KojimaDepartment of Surgery, Division of Vascular Surgery, Stanford University School of Medicine, Stanford, CA, USA.
Alice IngelssonDepartment of Surgery, Division of Vascular Surgery, Stanford University School of Medicine, Stanford, CA, USA.
Caitlin F BellDepartment of Surgery, Division of Vascular Surgery, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0001-7352-142X
Nicolas G LopezDepartment of Surgery, Division of Vascular Surgery, Stanford University School of Medicine, Stanford, CA, USA.
Changhao FuDepartment of Surgery, Division of Vascular Surgery, Stanford University School of Medicine, Stanford, CA, USA.
Ryan B ChoiDepartment of Surgery, Division of Vascular Surgery, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0003-2980-3977
Zach MillerDepartment of Biomedical Engineering, Michigan State University, East Lansing, MI, USA.
Leo BarriosDepartment of Biomedical Engineering, Michigan State University, East Lansing, MI, USA.
Susan WalshDivision of Cardiovascular Medicine, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA.
Ferhaan AhmadDivision of Cardiovascular Medicine, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA.
Lars MaegdefesselDepartment for Vascular and Endovascular Surgery, Klinikum rechts der Isar, Technical University, Munich, Germany.ORCID 0000-0001-5228-2634
Bryan Ronain SmithDepartment of Biomedical Engineering, Michigan State University, East Lansing, MI, USA. smit2901@msu.edu.ORCID 0000-0002-5990-2901
Nicholas J LeeperDepartment of Surgery, Division of Vascular Surgery, Stanford University School of Medicine, Stanford, CA, USA. nleeper@stanford.edu.ORCID 0000-0002-0905-2806

Funding

Medical Scientist Training Program Training GrantT32GM145449 · NIGMS · DUKE UNIVERSITY · PI Christopher D Kontos · 2022 to 2026
$6.6M
Clonal expansion, resistance to efferocytosis and innate immunity in atherosclerosisR35HL144475 · NHLBI · STANFORD UNIVERSITY · PI LEEPER, NICHOLAS JAMES · 2019 to 2024
$5.1M
Macrophage-specific nanotherapy for breast cancerR01CA244491 · NCI · OHIO STATE UNIVERSITY · PI Bryan Ronain Smith · 2020 to 2026
$2.5M
American Heart Association (American Heart Association, Inc.) 18TPA34230113American Heart Association (American Heart Association, Inc.) EIA34770065NCI NIH HHS R01 CA244491NHLBI NIH HHS R35 HL144475NIGMS NIH HHS T32 GM145449
6 · The paper itself

Abstract

Atherosclerosis is an inflammatory disorder responsible for cardiovascular disease. Reactivation of efferocytosis, the phagocytic removal of cells by macrophages, has emerged as a translational target for atherosclerosis. Systemic blockade of the key 'don't-eat-me' molecule, CD47, triggers the engulfment of apoptotic vascular tissue and potently reduces plaque burden. However, it also induces red blood cell clearance, leading to anemia. To overcome this, we previously developed a macrophage-specific nanotherapy loaded with a chemical inhibitor that promotes efferocytosis. Because it was found to be safe and effective in murine studies, we aimed to advance our nanoparticle into a porcine model of atherosclerosis. Here, we demonstrate that production can be scaled without impairing nanoparticle function. At an early stage of disease, we find our nanotherapy reduces apoptotic cell accumulation and inflammation in the atherosclerotic lesion. Notably, this therapy does not induce anemia, highlighting the translational potential of targeted macrophage checkpoint inhibitors.

Indexed as

AnemiaAtherosclerosisCD47 AntigenDisease Models, AnimalInflammationMacrophagesNanoparticlesPhagocytosisAnimalsApoptosisHumansMaleMicePlaque, AtheroscleroticSwineCD47 Antigen

Identifiers

PMID39271657
PMCPMC11399336

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.